A Study of Stem Cells and Filgrastim

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00001071
First received: November 2, 1999
Last updated: May 22, 2012
Last verified: May 2012
  Purpose

To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure.


Condition Intervention
HIV Infections
Drug: Filgrastim

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using Filgrastim

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 24
Study Completion Date: October 1998
Detailed Description:

Patients and volunteers receive seven daily subcutaneous injections of G-CSF. On days 5 and 6 of drug administration, patients have peripheral blood mononuclear cells harvested by leukapheresis. HIV-positive patients are stratified into three cohorts based on CD4 count and presence of symptoms. If no increase in number of harvested stem cells and no grade 4 bone pain toxicity occur in two of the first three patients in a cohort, then the last three patients in that cohort will receive a dose escalation. Patients are followed for 24 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • PCP prophylaxis.
  • Antiretroviral therapy in patients with CD4 counts <= 500 cells/mm3.
  • Narcotic analgesics for grade 3/4 bone pain toxicity.

Patients must have:

  • HIV infection.
  • HIV infected patients with CD4 count > 500 cells/mm3 must be asymptomatic. Patients with CD4 count 200-500 cells/mm3 may be either asymptomatic or symptomatic but must not have AIDS. Patients with CD4 count < 200 cells/mm3 may or may not have AIDS-defining conditions.
  • No antiretroviral therapy within the past 30 days in patients with asymptomatic disease and CD4 count > 500 cells/mm3.
  • Stable antiretroviral therapy for the past 60 days if CD4 count <= 500 cells/mm3.
  • Suitable venous access.

Prior Medication:

Allowed:

  • Prior antiretroviral therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Current malignancy.
  • Any medication condition that interferes with study evaluation.
  • Known hypersensitivity to E. coli-derived proteins (e.g., insulin, human growth hormones).

Concurrent Medication:

Excluded:

  • Acute treatment for serious opportunistic infection.
  • Systemic cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

  • Systemic radiation therapy.

Patients with the following prior conditions are excluded:

  • Prior malignancy.
  • Leukapheresis or lymphopheresis within the past 180 days.
  • Significant active CNS disease or seizures within the past year.

Prior Medication:

Excluded:

  • G-CSF or GM-CSF within the past 6 months.
  • Investigational antiretrovirals within the past 30 days.
  • Treatment for opportunistic infection within the past 14 days.

Active alcohol or substance abuse.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001071

Locations
United States, California
UCLA CARE Center CRS
Los Angeles, California, United States, 90095
United States, Colorado
University of Colorado Hospital CRS
Aurora, Colorado, United States
Sponsors and Collaborators
Investigators
Study Chair: Schooley R
Study Chair: Miles S
Study Chair: Pomerantz R
  More Information

Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00001071     History of Changes
Other Study ID Numbers: ACTG 285, 11261
Study First Received: November 2, 1999
Last Updated: May 22, 2012
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Granulocyte Colony-Stimulating Factor
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Stem Cells

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Lenograstim
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014